Developer docs
API playgroundTry for free, no card

Search company profiles

Orbit Discovery

Full company profile

uuid0002xps

Namestring
Orbit Discovery
Legal namestring
Orbit Discovery Ltd.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Orbit Discovery is a private peptide discovery services company spun out of the University of Oxford in 2016, headquartered at the Oxford Science Park. It provides fee-for-service affinity and functional screening of peptide libraries to pharmaceutical and biotechnology customers developing peptide therapeutics against targets including GPCRs, membrane proteins, soluble proteins, and tumour-associated antigens used in radiopharmaceutical and nucleic-acid-delivery applications. Its core platform combines a bead-based peptide display system — using in-emulsion in vitro transcription translation (emIVTT) to express peptides linked to encoding DNA on individual beads — with FACS-based affinity sorting and a proprietary droplet-microfluidic functional screening workflow that pairs single peptides with single reporter cells in micro-droplets. This architecture enables screening of millions of peptides per campaign, including linear, cyclic, and helical structures with high chemical diversity, and is differentiated from traditional phage and ribosomal display by its ability to identify functional modulators (agonists, antagonists, biased signalling) directly in cell-based assays rather than only binding hits.

The company operates a B2B enterprise sales motion targeting both Big Pharma and Small Biotech, with customisable service engagements covering radiopharmaceutical targeting, nucleic-acid delivery, targeted protein degradation, soluble protein targeting, and GPCR agonism/antagonism screening. Revenue is generated through professional-services contracts (fee-for-service) augmented by milestone or option structures on partnered programs; pricing is not publicly disclosed. As of late 2024, the company has secured multiple strategic collaborations — including expanded agreements with Evergreen Theragnostics (Dec 2024), Secarna Pharmaceuticals (May 2024), Orano Med (Sept 2023), Evergreen Discovery (April 2023), Endevica Bio (Feb 2023), SanegeneBio (Jan 2023), and a technology partnership with WuXi AppTec (Mar 2022) — establishing radiopharmaceutical targeting, nucleic-acid delivery, and GPCR discovery as its primary commercial verticals.

The company is privately held and backed by Oxford Sciences Innovation (now Oxford Science Enterprises), Borealis Ventures, Perivoli Innovations, Oxford University Innovation, and RT Ventures, following a $7.6M funding round in July 2021 supplemented by a £472K Innovate UK Smart Grant in June 2022. It is led by CEO Dr Neil Butt, with CTO Anthony Pitt overseeing technology operations and scientific founders Professor Graham Ogg and Professor Terry Rabbitts providing research continuity to the underlying bead-display IP.

Short descriptiontext

Orbit Discovery is a private UK peptide discovery CRO, spun out of the University of Oxford in 2016, that uses proprietary bead-based display and microfluidic functional screening to deliver affinity and cell-based screening services to pharmaceutical and biotechnology partners developing peptide therapeutics, including radiopharmaceutical, nucleic-acid-delivery, and GPCR-targeted programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide discovery services, bead-based peptide display, microfluidic functional screening, radiopharmaceutical targeting peptides, GPCR agonist screening
Industry3 codes
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Misc Health & Allied Services, Nec8090
Product category
Peptide Discovery Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Peptide Discovery Services
TypeProfessional Services
Description

Orbit Discovery provides fee-for-service peptide discovery services for therapeutic applications including radionuclide targeting, nucleic acid targeting, targeted protein degradation, soluble protein targeting, and GPCR agonism and antagonism. Services are customizable for both affinity screening and functional screening using proprietary reporter cell lines.

orbitdiscovery.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Orbit Discovery provides fee-for-service peptide discovery for therapeutic applications, combining a proprietary bead-based peptide display system with microfluidic high-throughput screening. The company delivers customizable affinity screening (using FACS against soluble targets, GPCRs, ion channels) and cell-based functional screening (identifying agonists and antagonists against reporter cell lines) across massive chemical spaces including linear and macrocyclic peptides. Service offerings are organized around four therapeutic application areas: radiopharmaceutical targeting, nucleic acid delivery, soluble protein targeting, and GPCR agonism/antagonism discovery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Screening millions of peptides in a single experiment vs. tens of thousands with traditional platforms
+1 more record
Product overview1 text field

Orbit Discovery operates as a peptide discovery services company built around its proprietary Orbit Peptide Discovery Platform. The platform combines bead-based display technology and microfluidics to perform high-throughput screening across massive chemical spaces. The core platform supports two main screening modalities: Affinity Screening Services (for identifying binders against soluble targets, GPCRs, and ion channels) and Functional Screening Services (for identifying functional agonists and antagonists in cell-based assays). These screening capabilities are applied through four application services: Radiopharmaceutical Targeting (for radionuclide delivery peptides), Nucleic Acid Delivery (for targeted RNA therapeutics), Soluble Protein Targeting (for PROTACs and molecular glues), and GPCR agonism/antagonism screening. The company serves pharmaceutical and biotechnology partners seeking peptide therapeutic candidates.

Product and service6 records
1Orbit Peptide Discovery Platform
CategoryCore platform / drug discovery technology
Description

The Orbit Peptide Discovery Platform is Orbit's core proprietary technology combining DNA-encoded bead-based peptide display with microfluidic screening for high-throughput affinity and functional screening of very large peptide libraries, including linear and macrocyclic peptides. It is used by Orbit's scientific team to deliver customised peptide discovery services to pharmaceutical and biotechnology partners.

2Affinity Screening Services
CategoryPeptide discovery service
Description

FACS-based high-throughput affinity screening service that interrogates large populations of bead-displayed peptides to identify binders against soluble protein targets, cell surface targets, GPCRs, and ion channels. Delivered to pharma and biotech clients seeking high-affinity peptide hits for downstream therapeutic development.

3Functional Screening Services
CategoryPeptide discovery service
Description

Microfluidic cell-based functional screening service that screens millions of peptides directly against reporter cell lines using a One Peptide: One Cell approach, enabling identification of GPCR agonists, antagonists, and other functional modulators rather than just binders. Sold to pharma and biotech clients needing biologically active peptide hits for therapeutic programmes.

4Radiopharmaceutical Targeting Services
CategoryApplication service — radiopharmaceuticals
Description

Application-specific peptide discovery service for radiopharmaceutical programmes. Combines bead-based display with flow cytometry to identify high-affinity peptide conjugates that deliver radionuclides to tumor-specific targets with high specificity and minimal off-target binding. Targeted at radiopharmaceutical developers, including partners such as Evergreen Theragnostics and Orano Med.

5Nucleic Acid Delivery Services
CategoryApplication service — nucleic acid therapeutics
Description

Application-specific peptide discovery service for targeted nucleic acid (RNA) delivery. Uses bead-based display and FACS screening to identify peptides with strong affinities for disease-specific targets and validates large numbers of peptides for cellular internalisation. Targeted at antisense oligonucleotide and RNAi therapeutics developers such as Secarna Pharmaceuticals and SanegeneBio.

6Soluble Protein Targeting Services
CategoryApplication service — soluble protein targeting / TPD
Description

Application-specific peptide discovery service targeting soluble proteins, including identification of actuators for Targeted Protein Degradation (PROTACs and molecular glues). Supports multiple selections, counter-target screening, and precise tuning to binding sites for coupling high-affinity binders to ubiquitin ligases. Sold to pharma and biotech clients developing degraders and other soluble protein modulators.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-03
Description

Expansion of research collaboration to find novel targeting peptides for radiopharmaceutical delivery. Expanded upon previous April 2023 agreement. Collaboration leverages Orbit's proprietary screening platform combined with Evergreen's expertise in radiopharmaceutical development and clinical translation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-28
Description

Collaboration to discover and develop peptide-based targeted antisense oligonucleotide (ASO) therapeutics. Leverages Orbit's bead-based peptide display engine for identification, screening, and selection of cyclic peptides specific to disease targets to be paired with Secarna's ASO molecules.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-11
Description

Collaboration to discover specific Peptide Receptor Radionuclide Therapies against cancer cells. Orbit deploys its bead-based peptide display engine to discover peptide leads specific to tumour-related targets. Orano Med focuses on subsequent development using lead-212 alpha emitter.

4Evergreen Discovery
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-04-03
Description

Collaboration to identify specific cell targeting peptides and advance development of novel radiopharmaceuticals. Agreement covers activities from designing peptide libraries, hit identification to hit validation to confirm cell surface binding properties.

orbitdiscovery.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

Multi-target research agreement to advance development of cachexia therapeutics. Collaboration aims to accelerate development of advanced GPCR-targeting therapeutics using Orbit's functional screening platform to identify peptide hits against selected library populations.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-01-05
Description

Master Service Agreement to identify tissue-specific delivery mechanisms for RNA therapeutics. Collaboration covers activities from hit ID to cell-based internalisation studies, with option for Sanegene to further develop resulting hits.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-03-07
Description

Agreement to access peptide discovery and optimisation technologies. Orbit gains access to WuXi AppTec's expertise in peptide optimisation, production, manufacturing, cell line and assay development, and biophysical analysis. First strategic technology link Orbit penned since formation in 2016.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Bicycle Therapeutics develops bicyclic peptide therapeutics (Bicycles) using a proprietary phage-display-like constrained peptide platform. It is the largest publicly traded peptide-discovery platform company and the closest large-scale comparable to Orbit's bead-display peptide approach.

2PeptiDream
TypeBroad incumbent
Description

PeptiDream operates the Peptide Discovery Platform System (PDPS), a non-standard peptide discovery platform serving major pharma partners. It is a direct functional analogue to Orbit as a discovery engine, with a much larger partner base and public-company scale.

TypeDirect peer
Description

Philogen designs and develops peptide-based targeting ligands for radiopharmaceutical delivery and other applications. Overlaps directly with Orbit's radiopharmaceutical targeting service and shares the same class of tumor-targeting peptide customers (e.g., Orano Med ecosystem).

TypeBroad incumbent
Description

GenScript offers peptide synthesis, screening, and discovery services to pharma/biotech. Comparable to Orbit as a peptide discovery service provider, but at vastly larger scale and broader service scope.

TypeDirect peer
Description

Nimble Therapeutics is a peptide discovery platform combining high-throughput chemistry with screening to discover therapeutic peptides against challenging targets. Directly comparable service model and target-class focus to Orbit.

TypeDirect peer
Description

Protagonist uses a proprietary peptide technology platform to discover and develop peptide therapeutics, with marketed product (Rusfertide) and pipeline assets. Comparable platform-to-product evolution path Orbit could pursue.

TypeBroad incumbent
Description

AbCellera operates an AI-powered antibody discovery platform serving pharma/biotech. Closely analogous business model (B2B discovery services, proprietary platform, repeat partners) but focused on antibodies rather than peptides.

TypeRegional player
Description

Creative Peptides provides custom peptide synthesis and peptide discovery services, primarily serving US and global biotech clients. Smaller-scale comparable CRO in the peptide discovery services market where Orbit competes.

TypeDirect peer
Description

IONTAS pioneered mammalian display for antibody discovery and was acquired by FairJourney Biologics in 2020. Closely analogous discovery platform company with similar services-based model; CEO Neil Butt's former company.

10Distributed Bio (Charles River Laboratories)
TypeBroad incumbent
Description

Distributed Bio offered antibody and peptide library/screening services before being acquired by Charles River Laboratories. Comparable B2B discovery platform model now operating inside a global CRO infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orbit Discovery

Peptide Discovery Servicesorbitdiscovery.com

Orbit Discovery is a private UK peptide discovery CRO, spun out of the University of Oxford in 2016, that uses proprietary bead-based display and microfluidic functional screening to deliver affinity and cell-based screening services to pharmaceutical and biotechnology partners developing peptide therapeutics, including radiopharmaceutical, nucleic-acid-delivery, and GPCR-targeted programs.

What Orbit Discovery does

Orbit Discovery is a private peptide discovery services company spun out of the University of Oxford in 2016, headquartered at the Oxford Science Park. It provides fee-for-service affinity and functional screening of peptide libraries to pharmaceutical and biotechnology customers developing peptide therapeutics against targets including GPCRs, membrane proteins, soluble proteins, and tumour-associated antigens used in radiopharmaceutical and nucleic-acid-delivery applications. Its core platform combines a bead-based peptide display system — using in-emulsion in vitro transcription translation (emIVTT) to express peptides linked to encoding DNA on individual beads — with FACS-based affinity sorting and a proprietary droplet-microfluidic functional screening workflow that pairs single peptides with single reporter cells in micro-droplets. This architecture enables screening of millions of peptides per campaign, including linear, cyclic, and helical structures with high chemical diversity, and is differentiated from traditional phage and ribosomal display by its ability to identify functional modulators (agonists, antagonists, biased signalling) directly in cell-based assays rather than only binding hits.

The company operates a B2B enterprise sales motion targeting both Big Pharma and Small Biotech, with customisable service engagements covering radiopharmaceutical targeting, nucleic-acid delivery, targeted protein degradation, soluble protein targeting, and GPCR agonism/antagonism screening. Revenue is generated through professional-services contracts (fee-for-service) augmented by milestone or option structures on partnered programs; pricing is not publicly disclosed. As of late 2024, the company has secured multiple strategic collaborations — including expanded agreements with Evergreen Theragnostics (Dec 2024), Secarna Pharmaceuticals (May 2024), Orano Med (Sept 2023), Evergreen Discovery (April 2023), Endevica Bio (Feb 2023), SanegeneBio (Jan 2023), and a technology partnership with WuXi AppTec (Mar 2022) — establishing radiopharmaceutical targeting, nucleic-acid delivery, and GPCR discovery as its primary commercial verticals.

The company is privately held and backed by Oxford Sciences Innovation (now Oxford Science Enterprises), Borealis Ventures, Perivoli Innovations, Oxford University Innovation, and RT Ventures, following a $7.6M funding round in July 2021 supplemented by a £472K Innovate UK Smart Grant in June 2022. It is led by CEO Dr Neil Butt, with CTO Anthony Pitt overseeing technology operations and scientific founders Professor Graham Ogg and Professor Terry Rabbitts providing research continuity to the underlying bead-display IP.

Orbit Discovery firmographics

Firmographics
Name
Orbit Discovery
Legal name
Orbit Discovery Ltd.
Website
https://orbitdiscovery.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Orbit Discovery is a private UK peptide discovery CRO, spun out of the University of Oxford in 2016, that uses proprietary bead-based display and microfluidic functional screening to deliver affinity and cell-based screening services to pharmaceutical and biotechnology partners developing peptide therapeutics, including radiopharmaceutical, nucleic-acid-delivery, and GPCR-targeted programs.
Ownership category
akta.pro rank

Orbit Discovery industry classification

Industry
Product category
Peptide Discovery Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Peptide discovery services
  • Bead-based peptide display
  • Microfluidic functional screening
  • Radiopharmaceutical targeting peptides
  • GPCR agonist screening

Where Orbit Discovery is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Orbit Discovery business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Peptide Discovery Services: Orbit Discovery provides fee-for-service peptide discovery services for therapeutic applications including radionuclide targeting, nucleic acid targeting, targeted protein degradation, soluble protein targeting, and GPCR agonism and antagonism. Services are customizable for both affinity screening and functional screening using proprietary reporter cell lines.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Orbit Discovery product offering

Product offering

Core offering

Orbit Discovery provides fee-for-service peptide discovery for therapeutic applications, combining a proprietary bead-based peptide display system with microfluidic high-throughput screening. The company delivers customizable affinity screening (using FACS against soluble targets, GPCRs, ion channels) and cell-based functional screening (identifying agonists and antagonists against reporter cell lines) across massive chemical spaces including linear and macrocyclic peptides. Service offerings are organized around four therapeutic application areas: radiopharmaceutical targeting, nucleic acid delivery, soluble protein targeting, and GPCR agonism/antagonism discovery.

Product overview

Orbit Discovery operates as a peptide discovery services company built around its proprietary Orbit Peptide Discovery Platform. The platform combines bead-based display technology and microfluidics to perform high-throughput screening across massive chemical spaces. The core platform supports two main screening modalities: Affinity Screening Services (for identifying binders against soluble targets, GPCRs, and ion channels) and Functional Screening Services (for identifying functional agonists and antagonists in cell-based assays). These screening capabilities are applied through four application services: Radiopharmaceutical Targeting (for radionuclide delivery peptides), Nucleic Acid Delivery (for targeted RNA therapeutics), Soluble Protein Targeting (for PROTACs and molecular glues), and GPCR agonism/antagonism screening. The company serves pharmaceutical and biotechnology partners seeking peptide therapeutic candidates.

Differentiator

Problem solved

Functional benefit

Products and services

  • Orbit Peptide Discovery Platform The Orbit Peptide Discovery Platform is Orbit's core proprietary technology combining DNA-encoded bead-based peptide display with microfluidic screening for high-throughput affinity and functional screening of very large peptide libraries, including linear and macrocyclic peptides. It is used by Orbit's scientific team to deliver customised peptide discovery services to pharmaceutical and biotechnology partners.
  • Affinity Screening Services FACS-based high-throughput affinity screening service that interrogates large populations of bead-displayed peptides to identify binders against soluble protein targets, cell surface targets, GPCRs, and ion channels. Delivered to pharma and biotech clients seeking high-affinity peptide hits for downstream therapeutic development.
  • Functional Screening Services Microfluidic cell-based functional screening service that screens millions of peptides directly against reporter cell lines using a One Peptide: One Cell approach, enabling identification of GPCR agonists, antagonists, and other functional modulators rather than just binders. Sold to pharma and biotech clients needing biologically active peptide hits for therapeutic programmes.
  • Radiopharmaceutical Targeting Services Application-specific peptide discovery service for radiopharmaceutical programmes. Combines bead-based display with flow cytometry to identify high-affinity peptide conjugates that deliver radionuclides to tumor-specific targets with high specificity and minimal off-target binding. Targeted at radiopharmaceutical developers, including partners such as Evergreen Theragnostics and Orano Med.
  • Nucleic Acid Delivery Services Application-specific peptide discovery service for targeted nucleic acid (RNA) delivery. Uses bead-based display and FACS screening to identify peptides with strong affinities for disease-specific targets and validates large numbers of peptides for cellular internalisation. Targeted at antisense oligonucleotide and RNAi therapeutics developers such as Secarna Pharmaceuticals and SanegeneBio.
  • Soluble Protein Targeting Services Application-specific peptide discovery service targeting soluble proteins, including identification of actuators for Targeted Protein Degradation (PROTACs and molecular glues). Supports multiple selections, counter-target screening, and precise tuning to binding sites for coupling high-affinity binders to ubiquitin ligases. Sold to pharma and biotech clients developing degraders and other soluble protein modulators.

Quantifiable outcome

  • Screening millions of peptides in a single experiment vs. tens of thousands with traditional platforms
  • +1 more outcomes

Companies that use Orbit Discovery

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Orbit Discovery technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Orbit Discovery partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and major.

  • Evergreen TheragnosticscoreStrategic or Co-development Partner · 3 December 2024Expansion of research collaboration to find novel targeting peptides for radiopharmaceutical delivery. Expanded upon previous April 2023 agreement. Collaboration leverages Orbit's proprietary screening platform combined with Evergreen's expertise in radiopharmaceutical development and clinical translation.
  • Secarna PharmaceuticalscoreStrategic or Co-development Partner · 28 May 2024Collaboration to discover and develop peptide-based targeted antisense oligonucleotide (ASO) therapeutics. Leverages Orbit's bead-based peptide display engine for identification, screening, and selection of cyclic peptides specific to disease targets to be paired with Secarna's ASO molecules.
  • Orano MedcoreStrategic or Co-development Partner · 11 September 2023Collaboration to discover specific Peptide Receptor Radionuclide Therapies against cancer cells. Orbit deploys its bead-based peptide display engine to discover peptide leads specific to tumour-related targets. Orano Med focuses on subsequent development using lead-212 alpha emitter.
  • Evergreen DiscoverymajorStrategic or Co-development Partner · 3 April 2023Collaboration to identify specific cell targeting peptides and advance development of novel radiopharmaceuticals. Agreement covers activities from designing peptide libraries, hit identification to hit validation to confirm cell surface binding properties.
  • Endevica BiomajorStrategic or Co-development Partner · 1 February 2023Multi-target research agreement to advance development of cachexia therapeutics. Collaboration aims to accelerate development of advanced GPCR-targeting therapeutics using Orbit's functional screening platform to identify peptide hits against selected library populations.
  • SanegeneBiomajorStrategic or Co-development Partner · 5 January 2023Master Service Agreement to identify tissue-specific delivery mechanisms for RNA therapeutics. Collaboration covers activities from hit ID to cell-based internalisation studies, with option for Sanegene to further develop resulting hits.
  • WuXi AppTeccoreTechnology or Integration · 7 March 2022Agreement to access peptide discovery and optimisation technologies. Orbit gains access to WuXi AppTec's expertise in peptide optimisation, production, manufacturing, cell line and assay development, and biophysical analysis. First strategic technology link Orbit penned since formation in 2016.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Orbit Discovery competitors and assessment

Company assessment

Broad incumbents

  • Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide therapeutics (Bicycles) using a proprietary phage-display-like constrained peptide platform. It is the largest publicly traded peptide-discovery platform company and the closest large-scale comparable to Orbit's bead-display peptide approach.
  • PeptiDream: PeptiDream operates the Peptide Discovery Platform System (PDPS), a non-standard peptide discovery platform serving major pharma partners. It is a direct functional analogue to Orbit as a discovery engine, with a much larger partner base and public-company scale.
  • GenScript ProBio: GenScript offers peptide synthesis, screening, and discovery services to pharma/biotech. Comparable to Orbit as a peptide discovery service provider, but at vastly larger scale and broader service scope.
  • AbCellera Biologics: AbCellera operates an AI-powered antibody discovery platform serving pharma/biotech. Closely analogous business model (B2B discovery services, proprietary platform, repeat partners) but focused on antibodies rather than peptides.
  • Distributed Bio (Charles River Laboratories): Distributed Bio offered antibody and peptide library/screening services before being acquired by Charles River Laboratories. Comparable B2B discovery platform model now operating inside a global CRO infrastructure.

Direct peers

  • Philogen: Philogen designs and develops peptide-based targeting ligands for radiopharmaceutical delivery and other applications. Overlaps directly with Orbit's radiopharmaceutical targeting service and shares the same class of tumor-targeting peptide customers (e.g., Orano Med ecosystem).
  • Nimble Therapeutics: Nimble Therapeutics is a peptide discovery platform combining high-throughput chemistry with screening to discover therapeutic peptides against challenging targets. Directly comparable service model and target-class focus to Orbit.
  • Protagonist Therapeutics: Protagonist uses a proprietary peptide technology platform to discover and develop peptide therapeutics, with marketed product (Rusfertide) and pipeline assets. Comparable platform-to-product evolution path Orbit could pursue.
  • IONTAS (FairJourney Biologics): IONTAS pioneered mammalian display for antibody discovery and was acquired by FairJourney Biologics in 2020. Closely analogous discovery platform company with similar services-based model; CEO Neil Butt's former company.

Regional players

  • Creative Peptides: Creative Peptides provides custom peptide synthesis and peptide discovery services, primarily serving US and global biotech clients. Smaller-scale comparable CRO in the peptide discovery services market where Orbit competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Orbit Discovery social profiles

Digital presence

Orbit Discovery financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orbit Discovery leadership team

Management profile

Number of profiles

Profiles10 records

Orbit Discovery funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orbit Discovery M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orbit Discovery

What does Orbit Discovery do?

Orbit Discovery provides fee-for-service peptide discovery for therapeutic applications, combining a proprietary bead-based peptide display system with microfluidic high-throughput screening. The company delivers customizable affinity screening (using FACS against soluble targets, GPCRs, ion channels) and cell-based functional screening (identifying agonists and antagonists against reporter cell lines) across massive chemical spaces including linear and macrocyclic peptides. Service offerings are organized around four therapeutic application areas: radiopharmaceutical targeting, nucleic acid delivery, soluble protein targeting, and GPCR agonism/antagonism discovery.

Is Orbit Discovery a public or private company?

Orbit Discovery is a private company. It is classified as venture growth investor backed and is currently operating.

When was Orbit Discovery founded?

Orbit Discovery was founded in 2016. It employs 11 to 50 people.

Where is Orbit Discovery based?

Orbit Discovery is headquartered in Oxford, United Kingdom, in the Europe region.

How does Orbit Discovery make money?

One revenue line is on record: peptide Discovery Services.

Who are Orbit Discovery's main competitors?

Broad incumbents on record are Bicycle Therapeutics, PeptiDream, GenScript ProBio, AbCellera Biologics and Distributed Bio (Charles River Laboratories). Direct peers are Philogen, Nimble Therapeutics, Protagonist Therapeutics and IONTAS (FairJourney Biologics). Creative Peptides is listed as a regional player.

Does Orbit Discovery have an API?

No public API is recorded for Orbit Discovery.

What industry is Orbit Discovery in?

Orbit Discovery's product category is Peptide Discovery Services. Its primary akta.pro industry code is HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 5417 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceGPCRs, radiopharma and the rise of functional peptide screeningRenewed pharmaceutical industry interest in GPCR (G protein-coupled receptor) biology and radioligand therapies is driving attention to functional peptide screening platforms as potential differentiators in the crowded AI drug discovery market. Eli Lilly paid $140 million upfront to Radionetics Oncology in July 2024, securing exclusive rights to acquire the biotech for $1 billion and access novel GPCR targets. The global peptide library screening services market was projected to reach $50 billion, with companies like Orbit Discovery offering functional screening platforms that identify peptide agonists capable of inducing conformational changes needed to activate GPCR signaling pathways.openPR.comLeading Companies Consolidating Their Presence in the Antisense and RNAi Therapeutics MarketThe antisense and RNAi therapeutics market is projected to reach $3.53 billion by 2030, growing at a compound annual growth rate of 12.9%, driven by advancements in drug delivery technologies, precision medicine adoption, and increasing RNAi-based clinical trials. In July 2023, Alnylam Pharmaceuticals announced a strategic alliance with Roche AG to jointly develop and commercialize Zilebesiran, an investigational RNAi therapeutic for hypertension in patients with elevated cardiovascular risk. In January 2023, Orbit Discovery Limited partnered with SanegeneBio Inc. to identify tissue-specific delivery mechanisms for RNA therapeutics through hit identification and cell-based internalization studies.EIN PresswireAntisense & RNAi Therapeutics Market 2025-2029: Unveiling Growth Developments with the Latest UpdatesThe Business Research Company has published a market report projecting the global antisense and RNAi therapeutics market to grow from $1.75 billion in 2024 to $1.93 billion in 2025, and further to $3.11 billion by 2029, driven by a CAGR of 10.2% and 12.8% respectively. Key growth drivers include increased funding, technological advancements, rising healthcare expenditures, a growing elderly population, and heightened demand for RNA therapeutics accelerated by the COVID-19 pandemic. Notable trends include intensified R&D for rare diseases, nanoparticle applications, and strategic collaborations such as the January 2023 partnership between Orbit Discovery Limited and SanegeneBio Inc. for tissue-specific RNA therapeutics delivery.Drug Discovery World (DDW)Drug Discovery World (DDW)The article discusses advancements in drug discovery through AI, automation, and collaboration between companies such as Evergreen Discovery and Orbit Discovery to identify cell targeting peptides for radiopharmaceutical development. It also promotes upcoming webinars and podcasts focused on fragment-based drug discovery (FBDD) and biotechnology applications in drug discovery.Business Wire BlogOrbit Discovery and Evergreen Theragnostics Expand Research Collaboration to Advance Targeted Therapeutics DevelopmentOrbit Discovery and Evergreen Theragnostics extended their research collaboration to identify novel peptides for radiopharmaceutical delivery, building on a 2023 agreement. The partnership will use Orbit's screening platform and Evergreen's radiopharmaceutical expertise to accelerate clinical applications. Orbit Discovery will attend the Biotech Showcase in San Francisco and BIO-Europe in Milan in 2025.Drug Discovery World (DDW)Collaboration to discover novel targeted radioligand therapiesOrano Med and Orbit Discovery have entered into a collaboration to discover peptide receptor radionuclide therapies (PRRT) for cancer treatment using Lead-212 alpha therapy. Under the agreement, Orbit will deploy its bead-based peptide display engine to identify peptide candidates specific to tumour-associated targets, while Orano Med will handle clinical development after peptide conjugation with lead-212. The global targeted radiotherapies market is projected to grow at a CAGR of 30% between 2023 and 2030.News-MedicalOrbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticalsEvergreen Discovery and Orbit Discovery announced a collaboration to identify cell-targeting peptides for novel radiopharmaceuticals. The partnership will use Orbit's DNA-encoded library platform to screen libraries and validate binding, with Evergreen advancing clinical development. Orbit will present at TIDES and BIO International in 2023.dlvr.itSanegeneBio and Orbit join forces to establish targeting peptidesSanegeneBio and Orbit Discovery announced a partnership to develop RNAi therapeutics with tissue-specific delivery. The agreement covers cell-based internalisation studies and an option to further develop screening hits. The collaboration aims to accelerate Sanegene's RNAi portfolio into the clinic.News-MedicalOrbit Discovery awarded Innovate UK grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discoveryOrbit Discovery received a £472,000 Innovate UK Smart grant to expand its peptide drug discovery platform with droplet-based microfluidics. The project aims to screen millions of peptides in cell-based assays, improving efficiency and reducing costs for peptide therapeutics.BioSpaceOrbit Discovery and WuXi AppTec Sign Agreement to Access Peptide Discovery and Optimisation TechnologiesOrbit Discovery announced a partnership with WuXi AppTec to access peptide optimization, production, and manufacturing capabilities. The collaboration aims to help partners obtain clinically relevant data packs and materials rapidly, and is the first strategic technology link Orbit has formed since 2016.